A report by Tel Aviv University on Thursday showed that Israeli researchers have developed a treatment that could prevent developmental decline and autism. By Xinhua Net reportResearch was conducted with the mouse model. They have also found that early treatment with peptide NAP (nucleosome montage protein) normalizes the development of ADNP (activity-dependent neuroprotective protein) syndrome in children. One of the main causes of developmental delay and autism in children is genetic mutation.
The ADNP gene is involved in the development of cognition. In most cases, partial ADNP-deficient embryos will suffer from mental retardation and autism.
In recent years, autistic children with mental retardation had random mutations in the ADNP gene with the development of genetic sequencing technology, which appeared during pregnancy.
The resulting protein is shorter than normal and as a result, children suffer from incomplete ADNP (ADNP syndrome).
According to the report, the researchers found that mice with ADNP produce about half of the number of synapses (linking points between nerve cells) compared to brain areas responsible for cognitive activity, especially in mice.
These mice showed developmental delay, social difficulty and sensitivity as children with mental retardation and autism.
In the next step, after nasal spray was administered to mice sucked from the NAP peptide, they were injected daily into the affected mice daily.
However, the results were very impressive: treated mice developed normally. They were able to distinguish between familiar and unfamiliar mice, and developed proper memory and strength in their muscles. In fact, the brains of these mice began to produce the appropriate number of synapses.
Posted on: November 16, 2018 2:42 pm